Literature DB >> 26094595

Hypoxia in astrocytic tumors and implications for therapy.

David A Cavazos1, Andrew J Brenner2.   

Abstract

Glioblastoma (GBM, Grade IV astrocytoma) is the most common and most aggressive of the primary malignant brain tumors in adults. Hypoxia is a distinct feature in GBM and plays a significant role in tumor progression, resistance to treatment and poor outcomes. This review considers the effects of hypoxia on astrocytic tumors and the mechanisms that contribute to tumor progression and therapeutic resistance, with a focus on the vascular changes, chemotaxic signaling pathways and metabolic alterations involved.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acetate; Aerobic glycolysis; Astrocytic tumors; CXCL12; CXCR7; Glioblastoma multiforme; Hypoxia; Metabolic derangement; Pseudopalisading necrosis; TH-302

Mesh：

Year:  2015        PMID： 26094595      PMCID： PMC4684800          DOI： 10.1016/j.nbd.2015.06.007

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN： 0969-9961            Impact factor:   5.996


  56 in total

1.  Very long-chain fatty acids in peroxisomal disease.

Authors:  A Poulos; K Beckman; D W Johnson; B C Paton; B S Robinson; P Sharp; S Usher; H Singh
Journal:  Adv Exp Med Biol       Date:  1992       Impact factor: 2.622

2.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.

Authors:  P Kunkel; U Ulbricht; P Bohlen; M A Brockmann; R Fillbrandt; D Stavrou; M Westphal; K Lamszus
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

Review 3.  Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases.

Authors:  Laetitia Cartier; Oliver Hartley; Michel Dubois-Dauphin; Karl-Heinz Krause
Journal:  Brain Res Brain Res Rev       Date:  2005-02

4.  CXCL12 mediates apoptosis resistance in rat C6 glioma cells.

Authors:  Kirsten Hattermann; Rolf Mentlein; Janka Held-Feindt
Journal:  Oncol Rep       Date:  2012-02-06       Impact factor: 3.906

Review 5.  Hypoxia helps glioma to fight therapy.

Authors:  Verena Amberger-Murphy
Journal:  Curr Cancer Drug Targets       Date:  2009-05       Impact factor: 3.428

6.  CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

Authors:  Zhenhua Miao; Kathryn E Luker; Bretton C Summers; Rob Berahovich; Mahaveer S Bhojani; Alnawaz Rehemtulla; Celina G Kleer; Jeffrey J Essner; Aidas Nasevicius; Gary D Luker; Maureen C Howard; Thomas J Schall
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-26       Impact factor: 11.205

7.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.

Authors:  Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

8.  Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.

Authors:  John M L Ebos; Christina R Lee; James G Christensen; Anthony J Mutsaers; Robert S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

Review 9.  The radiotherapeutic injury--a complex 'wound'.

Authors:  James W Denham; Martin Hauer-Jensen
Journal:  Radiother Oncol       Date:  2002-05       Impact factor: 6.280

Review 10.  Development of HIF-1 inhibitors for cancer therapy.

Authors:  Barbara Onnis; Annamaria Rapisarda; Giovanni Melillo
Journal:  J Cell Mol Med       Date:  2009-08-08       Impact factor: 5.310
View more
  14 in total

Review 1.  Metabolomic signature of brain cancer.

Authors:  Renu Pandey; Laura Caflisch; Alessia Lodi; Andrew J Brenner; Stefano Tiziani
Journal:  Mol Carcinog       Date:  2017-07-17       Impact factor: 4.784

Review 2.  Targeting hypoxic response for cancer therapy.

Authors:  Elisa Paolicchi; Federica Gemignani; Marija Krstic-Demonacos; Shoukat Dedhar; Luciano Mutti; Stefano Landi
Journal:  Oncotarget       Date:  2016-03-22

3.  A Large-Scale RNAi Screen Identifies SGK1 as a Key Survival Kinase for GBM Stem Cells.

Authors:  Shreya Kulkarni; Surbhi Goel-Bhattacharya; Sejuti Sengupta; Brent H Cochran
Journal:  Mol Cancer Res       Date:  2017-10-09       Impact factor: 5.852

4.  Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study.

Authors:  Andrew Brenner; Richard Zuniga; Jessica D Sun; John Floyd; Charles P Hart; Stew Kroll; Lisa Fichtel; David Cavazos; Laura Caflisch; Aleksandra Gruslova; Shiliang Huang; Yichu Liu; Alessia Lodi; Stefano Tiziani
Journal:  Neuro Oncol       Date:  2018-08-02       Impact factor: 12.300

5.  Hypoxia Can Induce Migration of Glioblastoma Cells Through a Methylation-Dependent Control of ODZ1 Gene Expression.

Authors:  Carlos Velásquez; Sheila Mansouri; Olga Gutiérrez; Yasin Mamatjan; Pilar Mollinedo; Shirin Karimi; Olivia Singh; Nuria Terán; Juan Martino; Gelareh Zadeh; José L Fernández-Luna
Journal:  Front Oncol       Date:  2019-10-10       Impact factor: 6.244

Review 6.  Glioblastoma Metabolomics-In Vitro Studies.

Authors:  Karol Jaroch; Paulina Modrakowska; Barbara Bojko
Journal:  Metabolites       Date:  2021-05-13

7.  Online database for brain cancer-implicated genes: exploring the subtype-specific mechanisms of brain cancer.

Authors:  Min Zhao; Yining Liu; Guiqiong Ding; Dacheng Qu; Hong Qu
Journal:  BMC Genomics       Date:  2021-06-18       Impact factor: 3.969

8.  Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches.

Authors:  Wen-Juan Huang; Wei-Wei Chen; Xia Zhang
Journal:  Oncol Lett       Date:  2016-08-04       Impact factor: 2.967

9.  A Chimeric Antibody against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models.

Authors:  Nicole Salazar; Jeffrey C Carlson; Kexin Huang; Yayue Zheng; Cecilia Oderup; Julia Gross; Andrew D Jang; Thomas M Burke; Susanna Lewén; Alexander Scholz; Serina Huang; Leona Nease; Jon Kosek; Michel Mittelbronn; Eugene C Butcher; Hua Tu; Brian A Zabel
Journal:  Mol Ther       Date:  2018-03-06       Impact factor: 11.454

10.  LOXL2 Upregulation in Gliomas Drives Tumorigenicity by Activating Autophagy to Promote TMZ Resistance and Trigger EMT.

Authors:  Qing Zhang; Lianhe Yang; Gefei Guan; Peng Cheng; Wen Cheng; Anhua Wu
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.